Introduction
Burkholderia cepacia is an aerobic, glucose-non-fermenting, gram-negative bacillus that mainly affects immunocompromised and hospitalized patients as well as those with chronic granulomatous disease and cystic fibrosis [1] [2] [3] . There have also been reports of B. cepacia causing endocarditis, infections of the central nervous system, and neonatal sepsis [2] [3] [4] . This organism is not normal human flora, and is usually found in hospital environments, such as in contaminated disinfectants, nebulizer solutions, medical devices, and on www.chikd.org the skin of healthcare workers 3, [5] [6] [7] . Recently, B. cepacia infections have increased because of increased use of broad-spectrum antimicrobial agents, longer duration of hospitalization and indwelling device-related infections 4, 7, 8) . This organi sm has high levels of resistance to many antimicrobial agents, and sulfamethoxazole-trimethoprim has been the drug of choice for treatment 1, 4) . There have been rare reports of urinary tract infection (UTI) caused by B. cepacia. Hosts with predisposing factors, such as post renal transplant, vesico-ureteral reflux (VUR), neurogenic bladder, bladder irrigation, or use of contaminated medical devices, have been reported to be susceptible to B. cepacia UTI [9] [10] [11] . We sought to analyze the incidence, clinical manifestations, risk factors, antimicrobial sensitivity and outcomes of B. cepacia UTI in pediatric patients.
Methods
This retrospective study was conducted at Samsung Medical Center, a tertiary referral hospital in Seoul, Republic of Korea. Patients with urine culture-proven B. cepacia UTI between January 2000 and December 2014 were included in the retrospective analysis of medical records. Urinary tract infection was defined as a positive urine test plus at least one of the symptoms or signs of infection, including temperature > 38℃, dysuria, or costovertebral angle tenderness. A positive urine test was defined as a urine culture with ≥ 10 5 colony forming units (CFU)/mL of B.
cepacia from a urine sample collected either via catheter (if during the catheterization period), or by voiding (if the age was more than 3 years) or intermittent catheterization (if the age was less than 3 years 
Host factors for B. cepacia UTI
The characteristics of the studied patients are presented in Table 1 . Of 14 patients with UTI, 11 patients were admitted to the pediatric intensive care unit. Nine of these 11 patients had a bladder catheter (Foley) in place when urine culture grew B. cepacia. Patients had multiple predisposing factors for UTI, including double-J catheter insertion, VUR, congenital heart disease, or malignancy.
1) Catheter-related infection
Two patients developed double-J catheter-related B. cepacia UTIs, and were treated with parenteral antimicrobial agents. Subsequent urine culture was negative after treatment, and they were discharged after the removal of the double-J catheter. During follow-up, they did not develop recurrent UTI.
2) Vesico-ureteral reflux-associated infection Four patients with VUR developed B. cepacia UTI. A 1-month-old girl with a cloaca anomaly associated VUR developed UTI after colostomy operation. A subsequent urine culture was negative after the treatment, and she was discharged with no further antimicrobial agents. During follow-up, the patient did not develop recurrent UTI. A 2-month-old boy with bilateral VUR grade IV developed B. cepacia UTI in spite of chemoprophylaxis, and follow- www.chikd.org up urine culture was negative after the treatment. He suffered from recurrent UTI, and ureteroneocystostomy was performed at the age of 18 months. A 2-year-old boy with Rubinstein-Taybe syndrome and bilateral VUR developed B. cepacia UTI after the operation of ureteroneo cystostomy under the condition of PCN. After the treatment, he was discharged after removal of PCN, and did not suffer from recurrent UTI. Finally, a 1-month-old boy with ventricular septal defect (VSD) and a single kidney associated with VUR developed B. cepacia UTI despite the use of a third-generation cephalosporin, and levofloxacin was given intravenously for 14 days, and the infection resolved.
3) Congenital heart disease and prolonged catheterization Four patients with congenital heart disease were diagnosed with B. cepacia UTI from bladder catheter urine samples. Three patients were admitted to the pediatric intensive care unit for congenital heart disease repair, and febrile UTI developed while a bladder catheter was in place after the operation. They were treated with intravenous antimicrobial, and the subsequent urine culture showed no growth. Finally, a 2-month-old boy with total anomalous pulmonary venous return was admitted to the pediatric intensive care unit because of severe respiratory distress. While in the intensive care unit receiving mechanical ventilation, he developed fever despite use of a third-generation cephalosporin. His urine sample from a bladder catheter grew over 10 5 CFU/mL of B. cepacia. The patient was treated with parenteral meropenem for 14 days. The subsequent urine culture was negative, but he died of uncompensated respiratory failure.
4) Immunocompromised hosts
Three patients had malignancies including leukemia, glioblastoma, and neuroblastoma, and 2 patients with leukemia and neuroblastoma were on chemotherapy. A 12-year-old girl with acute lymphoblastic leukemia developed B. cepacia UTI during treatment with parenteral antimicrobial agents (cefotaxime and amikacin). She was treated with parenteral imipenem for 14 days, and follow-up urine culture did not grow any organisms. Unfortunately, she died of uncontrolled sepsis. Next, an 18-year-old girl with glioblastoma developed B. cepacia UTI after tumor removal, and treated with parenteral piperacillin-tazobac tam for 14 days. The subsequent urine culture was negative. An 8-day-old girl with prenatally diagnosed neuroblastoma developed B. cepacia UTI after the first cycle of chemotherapy during the use of empirical antimicro bial agents (cefotaxime and amikacin). The antimicrobial agents were changed to parenteral meropenem, and urine culture demonstrated clearance after treatment. Finally, a 3-monthold boy who was born at a gestational age of 25+2 weeks developed B. cepacia UTI during the hospitaliza tion of neonatal intensive care unit. He was treated with oral cefdinir, and follow-up urine culture was negative. He improved clinically and was discharged without the need for further antimicrobial agents.
Antimicrobial susceptibility pattern of B. cepacia
Pediatric patients were treated with piperacillin-tazobactam, ceftazidime, meropenem, levof loxacin, sulfamethoxazole-trimethoprim, and other third-generation cephalosporins for 7 to 14 days. Most patients were treated with parenteral antimicrobial agents. Follow-up urine cultures were sterile in all patients after this treatment period. The antimicrobial sensitivity pattern of B. cepacia is shown in Figure 2 . B. cepacia isolates were sensitive to piperacillintazobactam and sulfamethoxazole-trimethoprim, and resistant to amikacin and colistin.
Discussion
Burkholderia cepacia usually causes nosocomial infections in immunocompromised hosts, and the most common infectious focus is the respiratory tract, followed by intravascular catheters 2, 3, 8) . Burkholderia cepacia survives in moist environments, and outbreaks of B. cepacia infection have been described in association with contaminated nebulizers, indigo-carmine dye, mouthwash, and moisturizing body milk 3, [5] [6] [7] . In our study, the incidence of B. cepacia in 2014 was relatively high, and surveillance cultures for intensive care unit environments were conducted; however, negative results were found.
There have been few reports of the characteristics of B. cepacia UTI. Affected patients often have predisposing factors, such as renal transplantation, prolonged bladder catheterization, or urethrocystoscopy [9] [10] [11] . In our study, predis posing host factors such as prolonged genitourinary cathe terization, VUR, congenital heart disease, and immunocompromised status were suggested. Twelve of 14 patients with B. cepacia UTI had genitourinary catheterization such as bladder catheter, PCN, or double-J stents. Zeeshan et al. reported that VUR in a renal transplant recipient was a risk factor for B. cepacia UTI 11) . In our study, 4 patients (29%) showed VUR-related UTI in spite of prophylactic antimicrobial agents. VUR was also associated with other anomalies such as cloaca anomaly or chromosome abnormality. In cases of congenital heart disease, patients required prolonged pediatric intensive care unit stays and bladder catheterization, which increased their susce ptibility to B. cepacia UTI. In addition, immunocom promised oncology patients have been reported to be susceptible to B. cepacia infection 8) .
Burkholderia cepacia is a multidrug-resistant organism, and therapeutic options are limited 1) . Although trimethoprim-sulfamethoxazole has been the drug of choice, it is difficult to administer because of hypersensitivity, lack of availability, and resistance in some cases. Avgeri et al. reported that ceftazidime, meropenem, and piperacillin, either alone or in combination, may be used as alternative options in B. cepacia infections 1) . Patra et al. reported that piperacillin-tazobactam, ciprofloxacin, and trimethoprimsulfamethoxazole, either alone or in combination, could result in complete recovery of B. cepacia sepsis in neonates. 
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The highest susceptibility was observed with meropenem 4) . In our study, piperacillin-tazobactam, ceftazidime, trimethoprim-sulfamethoxazole, levofloxacin, and meropenem were used in the majority of cases. All patients experienced complete recovery from UTI. In our study, the highest susce ptibility was observed with piperacillin-tazobactam and trimethoprim-sulfamethoxazole. Importantly, there was 100% resistance to amikacin and colistin. Even so, Li et al. reported a case of B. cepacia UTI after renal transplan tation that required a graft nephre ctomy because B. cepacia showed in vivo resistance to all available antimicrobial agents, and long-term use of pipera cillin could not resolve the septic foci 9) . Because of such antimicrobial resistance, a combination of antimicrobial agents and surgical treatment in some cases may be required.
Burkholderia cepacia is a pathogen with intrinsic resistance to numerous antimicrobial agents that causes nosocomial UTI in pediatric patients with risk factors such as prolonged genitourinary catheterization, VUR, congenital heart disease, or malignancy. Prompt removal of catheters and appropriate antimicrobial therapy for B. cepacia UTI in high-risk patients can ensure complete recovery. In addition, a surveillance program for nosocomial infection in intensive care units is necessary to prevent B. cepacia infections.
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